Condition: Relapsed/Refractory Large B-Cell Lymphoma · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
This description comes directly from the study's public registry record.
Wei Liu, MD · +86 022-23608463 · liuwei@ihcams.ac.cn
Lugui Qiu, MD · +86 022-23908461 · qiulg@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology & Blood Disease Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06489808